The new service provides cosmetic, nutrition and pharmaceutical manufacturers with access to newly established, standardised test routines designed to discover and prove the biological effects of certain products. It also aims to discover unwanted reactions of ingredients in order to minimise health risk.
"In partnering, both companies see an ideal combination between expertise in development and automation of biological testing systems and their use in offering services in the newly developing market for the biological profiling of consumer product ingredients," said a CyBio spokesperson.
German-based firm BioTeSys has agreed to use its test systems, cell cultures and tools for data management under the new contract. CyBio Screening will share its knowledge and technologies for substance fragmentation, parallelisation and miniaturisation of biological test systems.
BioTeSys is a service-provider in the field of biological and chemical analysis. Its technology includes screening methods covering the detection of bioactive potential of substances and their mixtures, in vito-test systems based upon single cells, co-cultures or organotypic models as well as the design, performance, monitoring and validation of clinical studies.
CyBio handles service products for the automation of drug screening processes. It provides a broad range of solutions for pharmaceutical and agrochemical research, including liquid and plate handling, plate imaging and data handling. CyBio Screening is also a service provider in the area of drug discovery for pharmaceutical and agrochemical applications.